Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 170
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT06938854 | Investigational Study of SWM-831 to Treat Moderate and Severely Calcified Femoropopliteal Arteries | ||
| NCT07430917 | Safety and Efficacy of J147 in Acute Ischemic Stroke | ||
| NCT07525427 | Bactericidal Activity of TBD09 in Combination With Other Drugs in Pulmonary Tuberculosis | ||
| NCT03628235 | HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States | ||
| NCT03712345 | Safety and Efficacy Study of IFX-1 in add-on to Standard of Care in GPA and MPA | ||
| NCT03970837 | Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) | ||
| NCT05189977 | A Trial to Assess the Effects of Prazosin or Propranolol on Blood Pressure in the Presence of Brexpiprazole/Sertraline | ||
| NCT05508750 | Growth and Safety Clinical Trial on a New Infant Formula | ||
| NCT03980483 | Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate | ||
| NCT07000110 | Anifrolumab Malignancy and Serious Infections Study | ||
| NCT03956355 | Tapinarof for the Treatment of Plaque Psoriasis in Adults (3001) | ||
| NCT07517445 | Bactericidal Activity and Safety of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Drug-susceptible Pulmonary Tuberculosis | ||
| NCT04123574 | A Pilot Study of BXCL701 in Patients With Pancreatic Cancer | ||
| NCT03193476 | Registry for Patients With X-Linked Hypophosphatemia | ||
| NCT06024213 | A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy. | ||
| NCT02503033 | A Study of HMPL-523 in Relapsed or Refractory Hematologic Malignancies | ||
| NCT04625725 | Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult. | ||
| NCT06412250 | A Multicenter Observational Registry to Evaluate Safety and Performance of Vivo ISAR (SECURE Global Registry) | ||
| NCT04718103 | A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype | ||
| NCT05859854 | Cenobamate in Adults With Focal-Onset Seizures | ||
| NCT06951867 | Tezspire Cardiac Events PASS | ||
| NCT03464019 | Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT). | ||
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b | ||
| NCT03767075 | A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) | ||
| NCT04027439 | Study Evaluating 5 Doses of RPL554 and Placebo in COPD Patients Via a Dry Powder Inhaler | ||
| NCT04280029 | SELUTION SLR™ 014 In-stent Restenosis | ||
| NCT04134728 | Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors | ||
| NCT05925595 | Intra-articular Administration of Med Device Made of Biological Vegetal Matrix for the Treatment of Knee Osteoarthritis | ||
| NCT03077477 | Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers | ||
| NCT05169307 | CPX-351 Real-World Effectiveness and Safety Study | ||
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. | ||
| NCT06716801 | Real-world Clinical Response to Cenobamate Early add-on in France, Germany and Spain | ||
| NCT04025307 | Phase I Trial of bacTRL-IL-12 in Adult Subjects With Advanced, Treatment-refractory Solid Tumours | ||
| NCT07475468 | CP382 - Intermittent Catheter (IC) PRO Panel Plan | ||
| NCT04620148 | TAK-242 in Patients With Acute Alcoholic Hepatitis | ||
| NCT04206917 | MultiPulse Therapy (MPT) for AF | ||
| NCT04818801 | Safety, Reactogenicity and Immunogenicity Study of ReCOV | ||
| NCT04535986 | A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD | ||
| NCT03583164 | Evaluate F901318 (Olorofim) Treatment of Invasive Fungal Infections in Participants Lacking Treatment Options | ||
| NCT06203457 | Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome | ||
| NCT06973161 | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors | ||
| NCT07405983 | TOUCH® CMC 1 New Enrollment US Study | ||
| NCT03649152 | Safety and Effectiveness of Propagermanium in Focal Segmental Glomerulosclerosis Participants Receiving Irbesartan | ||
| NCT02104817 | Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia | ||
| NCT05782179 | Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Doses of GBS Vaccine in Elderly Participants | ||
| NCT05918978 | Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS | ||
| NCT03466320 | DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2 | ||
| NCT03566082 | Post-Approval Study of the R3 Biolox Delta Ceramic Acetabular System - Europe | ||
| NCT03838185 | Study to Assess the Safety, Tolerability and Pharmacokinetics of Single Ascending Oral Doses of J147 | ||
| NCT04246762 | Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 |
